<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html>
  <head>
    <title>serotonin</title>
    <meta name="generator" content="muse.el">
    <meta http-equiv="Content-Type"
          content="text/html; charset=iso-8859-1">
    
    
<link rel="stylesheet" type="text/css" charset="utf-8" media="all" href="common.css" />
<link rel="stylesheet" type="text/css" charset="utf-8" media="screen" href="screen.css" />
<link rel="stylesheet" type="text/css" charset="utf-8" media="print" href="~print.css" />

  </head>
  <body>

    <!-- Page published by Emacs Muse begins here -->
<h2>Serotonin</h2>

<h3>Part of</h3>

<p><a href="neurotransmitter.html">neurotransmitter</a>???</p>

<p><a href="neuromodulator.html">neuromodulator</a></p>



<h3>Aka</h3>

<p class="first">5-hydroxytryptamine</p>

<p>5-HT</p>



<h3>Function</h3>

<p class="first">believed to play an important role in the regulation of
mood, <a href="sleep.html">sleep</a>, emesis (vomiting), <a href="sexual%20behavior.html">sexual behavior</a> and appetite</p>



<h3>Source</h3>

<p class="first">synthezized from tryptophan (TRP)</p>

<blockquote>
<p class="quoted">does not cross the <a href="blood-brain%20barrier.html">blood-brain barrier</a> (e.g. if taken
orally), but tryptophan and its metabolite 5-HTP do</p>
</blockquote>

<p>neurons of the Raphe nuclei are the main source</p>



<h3>Details</h3>

<p class="first">uses <a href="metabotropic%20receptors.html">metabotropic receptors</a></p>



<h3>Clinical</h3>

<p class="first">involved in <a href="depression.html">depression</a>, migraine, <a href="bipolar%20disorder.html">bipolar disorder</a> and
anxiety, liver regeneration and cell division throughout the
body</p>



<h3>Sleep</h3>

<p class="first">precursor to <a href="melatonin.html">melatonin</a></p>



<h3>Neurotransmission</h3>

<p class="first">released from varicosities (swellings) long the <a href="axon.html">axon</a> rather
than synaptic terminal buttons</p>

<blockquote>
<p class="quoted">is this right???</p>
</blockquote>

<p>uptake through the specific monoamine transporter on the
presynaptic <a href="neuron.html">neuron</a></p>

<p>uptake reinhibitors:</p>

<blockquote>
<p class="quoted">MDMA (ecastasy)</p>
</blockquote>

<blockquote>
<p class="quoted"><a href="cocaine.html">cocaine</a></p>
</blockquote>

<blockquote>
<p class="quoted">tricyclic ntidepressants</p>
</blockquote>

<blockquote>
<p class="quoted">selective <a href="serotonin.html">serotonin</a> <a href="reuptake.html">reuptake</a> inhibitors (SSRIs)</p>
</blockquote>



<h3>From prosem</h3>

<p class="first">barry jacobs studies it</p>

<p>huge range of functions</p>

<blockquote>
<p class="quoted">some motor</p>
</blockquote>

<blockquote>
<p class="quoted">psychological/depressive</p>
</blockquote>

<p>see <a href="neurotransmitter.html#diet">neurotransmitter#diet</a></p>



<h3>Serotonin syndrome</h3>


<p>from Lane &amp; Baldwin (1997)</p>

<blockquote>
<p class="quoted">The selective pharmacology of the selective <a href="serotonin.html">serotonin</a>
<a href="reuptake.html">reuptake</a> inhibitors (SSRIs) results in a lower potential
for pharmacodynamic drug interactions relative to other
antidepressants such as the tricyclic antidepressants
(TCAs) and monoamine oxidase inhibitors (MAOIs).However,
the SSRIs have been implicated in the development of the
<a href="serotonin.html">serotonin</a> syndrome-a potentially life-threatening
complication of treatment with psychotropic drugs. The
syndrome is produced most often by the concurrent use of
two or more drugs that enhance central nervous system
<a href="serotonin.html">serotonin</a> activity and often goes unrecognized because of
the varied and nonspecific nature of its clinical
features. The <a href="serotonin.html">serotonin</a> syndrome is characterized by
alterations in cognition (disorientation, confusion),
behavior (agitation, restlessness), autonomic nervous
system function (fever, shivering, diaphoresis, diarrhea),
and neuromuscular (<a href="ataxia.html">ataxia</a>, hyperreflexia, myoclonus)
activity. The difference between this syndrome and the
occurrence of adverse effects caused by <a href="serotonin.html">serotonin</a> <a href="reuptake.html">reuptake</a>
inhibitors alone is the clustering of the signs and
symptoms, their severity, and their duration. There are
important pharmacokinetic interactions between SSRIs and
other serotonergic drugs due principally to their effects
on the cytochrome P450(CYP) isoenzymes, the potential for
which varies widely amongst the SSRI group, which may
increase the likelihood of a pharmacodynamic
interaction. The exceptionally long washout period
required after fluoxetine discontinuation may cause
additional problems and/or inconvenience. Patients with
<a href="serotonin.html">serotonin</a> syndrome usually respond to discontinuation of
drug therapy and supportive care alone, but they may also
require treatment with an antiserotonergic agent such as
cyproheptadine, methysergide, and/or propranolol. To
reduce the occurrence, morbidity, and mortality of the
<a href="serotonin.html">serotonin</a> syndrome, it must be both prevented by prudent
pharmacotherapy and given prompt recognition when it is
present. (J Clin Psychopharmacol 1997;17:208-221).</p>
</blockquote>



<h3>Misc</h3>

<p class="first">etymology</p>

<blockquote>
<p class="quoted">discovered by Rapport (1948)</p>
</blockquote>

<blockquote>
<p class="quoted">misnomer</p>
</blockquote>

<blockquote>
<p class="quoted">thought to be a vasoconstricter in blood serum, i.e. a a
serum affecting vascular tone...</p>
</blockquote>

<p><a href="serotonin.html">serotonin</a> syndrome if you have too much</p>



<h3>Meeter et al (2006???)</h3>

<p class="first">5-HT implicated in</p>

<blockquote>
<p class="quoted"><a href="memory.html">memory</a> (Buhot et al, 2000)</p>
</blockquote>

<blockquote>
<p class="quoted">depletion of tryptophan -&gt; worse <a href="episodic%20memory.html">episodic memory</a> (Riedel
et al, 1999)</p>
</blockquote>

<blockquote>
<p class="quoted">5-HT depletion and 5-HT agonists can both -&gt; worse
<a href="memory.html">memory</a> performance</p>
</blockquote>

<blockquote>
<p class="quoted"><a href="depression.html">depression</a> (Naughton et al, 2000)</p>
</blockquote>

<p><a href="depression.html">depression</a> can also worsen <a href="memory.html">memory</a></p>

<blockquote>
<p class="quoted">effect of SSRIs on <a href="memory.html">memory</a> is complicated - see Meeter et
al (2006) discussion</p>
</blockquote>

<p>effects of <a href="serotonin.html">serotonin</a> on <a href="hippocampus.html">hippocampus</a></p>

<blockquote>
<p class="quoted">hyperpolarizing influence on principal cells</p>
</blockquote>

<blockquote>
<p class="quoted">afterhyperpolarizing (AHP) currents are downregulated</p>
</blockquote>

<ul>
<li>&gt; reduced adaptation in principal cells

<p>i think they say that this doesn't much affect episodic
<a href="memory.html">memory</a> performance</p></li>
</ul>

<p>7 types of <a href="serotonin.html">serotonin</a> receptors</p>

<p>model - based on Meeter et al, 2004</p>

<blockquote>
<p class="quoted">medial septal cholinergic node that released <a href="acetylcholine.html">acetylcholine</a>
to all layers</p>
</blockquote>

<blockquote>
<p class="quoted">theta and gamma oscillations</p>
</blockquote>

<blockquote>
<p class="quoted">cholinergic node was disinhibited only when entorhinal
input did not elicit any recall in <a href="hippocampus.html">hippocampus</a>,
i.e. for novel inputs</p>
</blockquote>

<blockquote>
<p class="quoted">i.e. automatically switches between</p>
</blockquote>

<center>
<p>encoding mode</p>
</center>

<center>
<p>high <a href="acetylcholine.html">acetylcholine</a> release</p>
</center>

<center>
<p>retrieval mode</p>
</center>

<center>
<p>low <a href="acetylcholine.html">acetylcholine</a> release</p>
</center>

<p>argue that this is largely because of the 5-HT_1A and 5-HT_3
receptors which regulate the selectivity  of retrieval</p>

<blockquote>
<p class="quoted">confirmed predictions with healthy subjects (e.g. with
tryptophan depletion or ipsipirone challenge)</p>
</blockquote>

<blockquote>
<p class="quoted">ipsapirone = 5-HT_1A agonist</p>
</blockquote>

<blockquote>
<p class="quoted">metachlorophenylpiperazine (m-CPP) = 5-HT_2C agonist</p>
</blockquote>

<blockquote>
<p class="quoted">doesn't factor into the Meeter et al (2006) model</p>
</blockquote>

<p>low 5-HT transmission</p>

<blockquote>
<p class="quoted">large amount of information being retrieved</p>
</blockquote>

<blockquote>
<p class="quoted">at the cost of activating irrelevant information</p>
</blockquote>

<blockquote>
<p class="quoted">more false alarms</p>
</blockquote>

<blockquote>
<p class="quoted">confirmed using tryptophan (TRP) depletion</p>
</blockquote>

<p>high 5-HT transmission</p>

<blockquote>
<p class="quoted">less retrieval</p>
</blockquote>

<blockquote>
<p class="quoted">lower recall</p>
</blockquote>

<blockquote>
<p class="quoted">fewer false alarms</p>
</blockquote>

<blockquote>
<p class="quoted">ipsapirone challenge</p>
</blockquote>

<blockquote>
<p class="quoted">increased recall in depressed people, but lowered it in
controls - also as predicted - why different for
depressed people???</p>
</blockquote>

<p>i think they say that the effects are strongest if the 5-HT
is modulated before encoding (see Meeter et al (2006)
discussion)???</p>

<p>manipulating 5-HT is supposed to affect <a href="cortisol.html">cortisol</a> response
(hypothalamic-pituitary-adrenal) axis</p>

<blockquote>
<p class="quoted">complicated whether this affects <a href="memory.html">memory</a></p>
</blockquote>

<blockquote>
<p class="quoted">they didn't deal with it in this study</p>
</blockquote>




<h3>References</h3>

<p><a href="http://en.wikipedia.org/wiki/Serotonin">wikipedia on serotonin</a></p>

<p>Meeter, Talamini, Schimitt, Riedel - The effects of 5-HT on
<a href="memory.html">memory</a> and the <a href="hippocampus.html">hippocampus</a></p>



<h3>From <a href="sara.html">sara</a> notes</h3>

<p><a href="serotonin.html">serotonin</a> (5-HT):</p>

<blockquote>
<p class="quoted">B4-B9 originate in the <a href="raphe%20nuclei.html">raphe nuclei</a> (of the <a href="brainstem.html">brainstem</a>; of
<a href="pons.html">pons</a>, dorsal and median <a href="raphe%20nuclei.html">raphe nuclei</a>) and project to whole
forebrain and <a href="thalamus.html">thalamus</a>. B1-3 project from <a href="medulla.html">medulla</a> to lower
<a href="brain.html">brain</a> stem and <a href="spinal%20cord.html">spinal cord</a>.  Modulates the perception of
<a href="pain.html">pain</a> and <a href="muscle.html">muscle</a> tone.</p>
</blockquote>

<blockquote>
<p class="quoted">5-HT pathways play an important regulatory role in
hypothalamic cardiovascular and themoregulatory control
and modulate the responsiveness of cortical neurons. Also:
wake-<a href="sleep.html">sleep</a> cycles, affective behavior, food intake, and
<a href="sexual%20behavior.html">sexual behavior</a>.</p>
</blockquote>




<!-- Page published by Emacs Muse ends here --> 

<hr>

<script language="javascript" src="footer.js">

  </body>
</html>
